KIAA1549 and pilocytic astrocytoma: Because of the high frequency of BRAF fusions, a patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model has been established for preclinical drug testing and has been used for selected MAPK and MEK inhibitor testing [23].